tiprankstipranks
Kinnate Biopharma (KNTE)
NASDAQ:KNTE

Kinnate Biopharma (KNTE) Technical Analysis

232 Followers

Technical Sentiment

Overall Consensus
Buy
13Bullish
6Neutral
3Bearish
Technical Analysis Consensus
Buy
4Bullish
6Neutral
0Bearish
Moving Average Consensus
Buy
9Bullish
0Neutral
3Bearish
Kinnate Biopharma’s (KNTE) Moving Averages Convergence Divergence (MACD) indicator is 0.04, suggesting Kinnate Biopharma is a Buy.
Kinnate Biopharma’s (KNTE) 20-Day exponential moving average is 2.61, while Kinnate Biopharma’s (KNTE) share price is $2.65, making it a Buy.
Kinnate Biopharma’s (KNTE) 50-Day exponential moving average is 2.52, while Kinnate Biopharma’s (KNTE) share price is $2.65, making it a Buy.

Kinnate Biopharma (KNTE) Pivot Points

May 08, 2024, 12:51 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
2.60
2.62
2.64
2.66
2.67
2.69
2.70
Fibonacci
2.62
2.63
2.64
2.66
2.67
2.68
2.69
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Kinnate Biopharma (KNTE) Moving Averages

May 08, 2024, 12:51 PM
Period
Simple
Exponential
MA5
2.65Sell
2.65Sell
MA10
2.65Sell
2.64Buy
MA20
2.61Buy
2.61Buy
MA50
2.49Buy
2.52Buy
MA100
2.39Buy
2.42Buy
MA200
2.26Buy
2.55Buy
Kinnate Biopharma’s (KNTE) 10-Day exponential moving average is 2.64, while Kinnate Biopharma’s (KNTE) share price is $2.65, making it a Buy.
Kinnate Biopharma’s (KNTE) 100-Day exponential moving average is 2.42, while Kinnate Biopharma’s (KNTE) share price is $2.65, making it a Buy.
Kinnate Biopharma’s (KNTE) stock price is $2.65 and Kinnate Biopharma’s (KNTE) 50-day simple moving average is 2.49, creating a Buy signal.
Kinnate Biopharma’s (KNTE) stock price is $2.65 and Kinnate Biopharma’s (KNTE) 100-day simple moving average is 2.39, creating a Buy signal.
Kinnate Biopharma’s (KNTE) stock price is $2.65 and Kinnate Biopharma’s (KNTE) 200-day simple moving average is 2.26, creating a Buy signal.

Kinnate Biopharma (KNTE) Technical Indicators

May 08, 2024, 12:51 PM
Name
Value
Implied Action
RSI (14)
62.47
Neutral
STOCH (9,6)
33.33
Neutral
STOCHRSI (14)
74.93
Neutral
MACD (12,26)
0.04
Buy
ADX (14)
36.15
Neutral
Williams %R
-26.67
Buy
CCI (14)
57.31
Neutral
ATR (14)
0.05
-
Ultimate Oscillator
42.65
Neutral
ROC
3.52
Buy
Kinnate Biopharma’s (KNTE) Relative Strength Index (RSI) is 62.47, creating a Neutral signal.
Kinnate Biopharma’s (KNTE) Trend Strength Indicator (ADX) is 36.15, creating a Neutral signal.
Kinnate Biopharma’s (KNTE) Commodity Channel Index (CCI) is 57.31, creating a Neutral signal.
Kinnate Biopharma’s (KNTE) Price Rate of Change (ROC) is 3.52, creating a Buy signal.

FAQ

Is KNTE a Buy, Hold, or Sell?
Based on KNTE’s technical indicators, KNTE is a Buy.
    What is KNTE’s RSI (14)?
    KNTE’s RSI (14) is 62.47, which suggests KNTE is a Neutral.
      What is KNTE’s MACD?
      KNTE’s MACD is 0.04, which suggests KNTE is a Buy.
        What is KNTE’s 5-day moving average?
        KNTE’s 5-day moving average is 2.65, which suggests KNTE is a Sell.
          What is KNTE’s 20-day moving average?
          KNTE 20-day moving average is 2.61, which suggests KNTE is a Buy.
            What is KNTE’s 50-day moving average?
            KNTE’s 50-day moving average is 2.49, which suggests KNTE is a Buy.
              What is KNTE’s 200-day moving average?
              KNTE’s 200-day moving average is 2.26, which suggests KNTE is a Buy.
                What is KNTE’s Williams % R (14)?
                KNTE’s Williams % R (14) is -26.67, which suggests KNTE is a Buy.
                  What is KNTE’s CCI (14)?
                  KNTE’s CCI (14) is 57.31, which suggests KNTE is a Neutral.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis